Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Cardiovascular Franchise Swells; Combo Waves Will Crest in 2009

Executive Summary

Abbott plans to submit a fixed-dose statin-fenofibrate combination with AstraZeneca's Crestor in 2009, the company reported during a June 18 sales and earnings call

You may also be interested in...



Merck’s Cordaptive “Not Approvable,” But Clark Not Giving Up On Combo

Although Merck's cholesterol combination Cordaptive failed to clear FDA on the first pass, the company is clear that FDA's decision does not signal the end of development for the cholesterol drug

Merck’s Cordaptive “Not Approvable,” But Clark Not Giving Up On Combo

Although Merck's cholesterol combination Cordaptive failed to clear FDA on the first pass, the company is clear that FDA's decision does not signal the end of development for the cholesterol drug

Humira sales growth

Sales of the TNF inhibitor grew 40 percent in the third quarter to $427 mil. in the U.S. compared to the year-ago period, Abbott reports. Humira (adalimumab), which recently underwent a successful launch for Crohn's disease, also gained share in the rheumatology, dermatology and gastroenterology markets (1"The Pink Sheet" July 23, 2007, p. 11). Worldwide Humira sales were $803 mil. in the quarter, up 48.5 percent from 2006, leading the company to predict 2007 sales of $3 bil. for Abbott's leading product. Overall, Abbott reports a 22.2 percent increase in global pharmaceutical sales and U.S. pharmaceutical sales rose 17.5 percent in the quarter...

Related Content

UsernamePublicRestriction

Register

PS048586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel